Court approves $7.25 billion Bayer settlement over claims Roundup weed killer caused cancer
Summary
A Missouri judge approved a settlement under which Bayer could pay up to $7.25 billion over 20 years to resolve thousands of U.S. claims linking Roundup to non-Hodgkin lymphoma. The deal covers people already diagnosed and people diagnosed in future years, while Bayer continues to deny that Roundup causes cancer.Key Facts
- The nationwide settlement covers current and future U.S. claims involving non-Hodgkin lymphoma.
- Eligible participants could receive an average of $10,000 to $165,000, based on factors including product use, age at diagnosis, and illness severity.
- Bayer acquired Roundup when it bought Monsanto in 2018.
- Glyphosate is Roundup’s active ingredient.
- The World Health Organization’s cancer research agency classified glyphosate as probably carcinogenic in 2015.
- The U.S. Environmental Protection Agency has said glyphosate is not likely to cause cancer in humans when used as directed.
- About 200,000 Roundup-related claims have been made against Bayer.
- The settlement approval could be appealed.
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.